Table 1.
Patient Group Characteristics
| Survivors | Non-survivors | |||
|---|---|---|---|---|
| Median age, y, range (n = number of patients with data) | 54.6, 30–75 (45) | 55.3, 24–81 (27) | ||
| Male sex, n (%) | 32/45 (71.1) | 15/27 (55.5) | ||
| Baseline median MELD score, IQR (n) | 19.8, 16.0–23.1 (38) | 23.6, 17.4–28.4 (20) | ||
| Total HAS given, median, IQR (n) | 850, 700–1500 (44) | 1000, 400–1600 (26) | ||
| Median days in trial, IQR (n) | 14, 8–15 (44) | 12, 4–15 (26) | ||
| No. with infection diagnosed at recruitment (%) | 16/45 (35.5) | 12/26 (48) | ||
| Prescribed antibiotics at recruitment, n (%) | 22/45 (49) | 17/26 (65) | ||
| No. with new infection during trial after HAS treatment for >48 h (%) | 9/45 (20) | 10/26 (37) | ||
| Renal dysfunction diagnosis during trial (%) | 0/44 (0.0) | 8/26 (30.8) | ||
| Alcohol consumption as etiology (%) | 43 (91) | 27 (100) | ||
| Active alcohol consumption at admission (%) | 20 (43) | 5 (19) | ||
| ACLF scores, n (%) | 0 | 35 (77.8) | 0 | 17 (63) |
| 1 | 6 (13.3) | 1 | 4 (14.8) | |
| 2 | 3 (6.7) | 2 | 3 (11.1) | |
| 3 | 1 (2.2) | 3 | 3 (11.1) | |
ACLF, acute-on-chronic liver failure; HAS, human albumin solution; IQR, interquartile range; MELD, Model for End-Stage Disease.